Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 266-273

  Lubamba, Bob ^a   Huaux, François ^a   Lebacq, Jean ^a   Marbaix, Etienne ^a   Dhooghe, Barbara ^a   Panin, Nadtha ^a   Wallemacq, Pierre ^a   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CF pharmacotherapy; CFTR; Cystic fibrosis; Immunomodulation; Inflammation; Phosphodiesterase type 5 inhibitor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BIOLOGICAL MARKER; CHEMOATTRACTANT; CHEMOKINE; CHLORIDE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VARDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENOTYPE; HYPOTHESIS; IMMUNOMODULATION; INFLAMMATION; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; MACROPHAGE; MACROPHAGE INFILTRATION; MACROPHAGE MIGRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PROTEIN LOCALIZATION; PSEUDOMONAS AERUGINOSA; WILD TYPE;

ANIMALS; ANIMALS, OUTBRED STRAINS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; IMMUNOMODULATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED CFTR; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PNEUMONIA; PSEUDOMONAS INFECTIONS; SULFONES; TRIAZINES;

EID: 84862503933     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.03.003     Document Type: Article

References (32)

1. Pillarisetti N., Williamson E., Linnane B., et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011, 184:75-81.
2. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133:489-495.
3. Downey D.G., Bell S.C., Elborn J.S. Neutrophils in cystic fibrosis. Thorax 2009, 64:81-88.
4. van Heeckeren A.M., Schluchter M.D., Xue W., Davis P.B. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med 2006, 173:288-296.
5. Freedman S.D., Weinstein D., Blanco P.G., et al. Characterization of LPS-induced lung inflammation in cftr-/- mice and the effect of docosahexaenoic acid. J Appl Physiol 2002, 92:2169-2176.
6. Legssyer R., Huaux F., Lebacq J., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006, 7:134.
7. Klotz T., Sachse R., Heidrich A., et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001, 19:32-39.
8. Lubamba B., Lecourt H., Lebacq J., et al. Preclinical evidence that sildenafil and vardenafil correct cystic fibrosis defects. Am J Respir Crit Care Med 2008, 177:506-515.
9. Lubamba B., Lebacq J., Reychler G., et al. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2011, 37:72-78.
10. Dechecchi M.C., Nicolis E., Mazzi P., et al. Modulators of sphingolipid metabolism reduce lung inflammation. Am J Respir Cell Mol Biol 2011, 45:825-833.
11. van Doorninck J.H., French P.J., Verbeek E., et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995, 14:4403-4411.
12. Nicklas W., Baneux P., Boot R., et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002, 36:20-42.
13. Corvol H., Fitting C., Chadelat K., et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003, 284:L997-L1003.
14. Salva P.S., Doyle N.A., Graham L., Eigen H., Doerschuk C.M. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996, 21:11-19.
15. Smart S.J., Casale T.B. TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. Am J Physiol 1994, 266:L238-L245.
16. Steinhorn R.H., Gordon J.B., Tod M.L. Site-specific effect of guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs. Crit Care Med 2000, 28:490-495.
17. Holzmann A., Manktelow C., Weimann J., Bloch K.D., Zapol W.M. Inhibition of lung phosphodiesterase improves responsiveness to inhaled nitric oxide in isolated-perfused lungs from rats challenged with endotoxin. Intensive Care Med 2001, 27:251-257.
18. Glynos C., Kotanidou A., Orfanos S.E., et al. Soluble guanylyl cyclase expression is reduced in LPS-induced lung injury. Am J Physiol Regul Integr Comp Physiol 2007, 292:R1448-R1455.
19. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., Kowalczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002, 300:559-566.
20. Poschet J.F., Timmins G.S., Taylor-Cousar J.L., et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293:L712-L719.
21. Wang T., Liu Y., Chen L., et al. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J 2009, 33:1122-1132.
22. Di A., Brown M.E., Deriy L.V., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8:933-952.
23. Meyer M., Huaux F., Gavilanes X., et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009, 41:590-602.
24. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
25. Reiniger N., Lee M.M., Coleman F.T., Ray C., Golan D.E., Pier G.B. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun 2007, 75:1598-15608.
26. Levy H., Murphy A., Zou F., et al. IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol 2009, 44:580-593.
27. Poschet J., Perkett E., Deretic V. Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. Trends Mol Med 2002, 8:512-519.
28. Poschet J.F., Skidmore J., Boucher J.C., Firoved A.M., Van Dyke R.W., Deretic V. Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells. J Biol Chem 2002, 277:13959-13965.
29. Toward T.J., Smith N., Broadley K.J. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004, 169:227-234.
30. Hertz A.L., Beavo J.A. Cyclic nucleotides and phosphodiesterases in monocytic differentiation. Handb Exp Pharmacol 2011, 204:365-390.
31. Tateya S., Rizzo N.O., Handa P., et al. Endothelial NO/cGMP/VASP Signaling Attenuates Kupffer Cell Activation and Hepatic Insulin Resistance Induced by High-Fat Feeding. Diabetes 2011, 60:2792-2801.
32. Lubamba B., Lebacq J., Lebecque P., et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009, 179:1022-1028.